GANX
Gain Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GANX
Gain Therapeutics, Inc.
A biotech company that develops novel allosteric binding sites and creating small molecule treatments
Biological Technology
06/26/2020
03/18/2021
NASDAQ Stock Exchange
23
12-31
Common stock
4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814
--
Gain Therapeutics, Inc., was incorporated in Delaware on June 26, 2020. The Company is a biotechnology company that develops novel small molecule therapies for the treatment of diseases in multiple therapeutic areas, including central nervous system (" CNS ") diseases, lysosomal storage disorders (" LSD "), metabolic disorders, and other diseases that can be targeted by protein degradation, such as oncology.
Company Financials
EPS
GANX has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.15, meeting expectations. The chart below visualizes how GANX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
